Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency
about
Latent KSHV Infected Endothelial Cells Are Glutamine Addicted and Require Glutaminolysis for SurvivalKSHV Latency Locus Cooperates with Myc to Drive Lymphoma in MiceEpstein-Barr virus (EBV) Rta-mediated EBV and Kaposi's sarcoma-associated herpesvirus lytic reactivations in 293 cells.Mechanisms of Kaposi's Sarcoma-Associated Herpesvirus Latency and ReactivationImmunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Induces the Oncogenic miR-17-92 Cluster and Down-Regulates TGF-β Signaling.Downregulation of Poly(ADP-Ribose) Polymerase 1 by a Viral Processivity Factor Facilitates Lytic Replication of Gammaherpesvirus.Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitorsComprehensive mapping and analysis of Kaposi's sarcoma-associated herpesvirus 3' UTRs identify differential posttranscriptional control of gene expression in lytic versus latent infection.Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the Myc gene to facilitate lytic replication.c-Myc-mediated overexpression of miR-17-92 suppresses replication of hepatitis B virus in human hepatoma cells.The role of metabolic reprogramming in γ-herpesvirus-associated oncogenesis.Cdk1 inhibition induces mutually inhibitory apoptosis and reactivation of Kaposi's sarcoma-associated herpesvirus.ZIC2 is Essential for Maintenance of Latency and is a Target of an Immediate-Early Protein during KSHV Lytic Reactivation.Epstein-Barr Virus Rta-Mediated Accumulation of DNA Methylation Interferes with CTCF Binding in both Host and Viral Genomes.Kaposi sarcoma-associated herpesvirus vIRF-3 protein binds to F-box of Skp2 protein and acts as a regulator of c-Myc protein function and stability.Endothelial cell malignancies: new insights from the laboratory and clinic.
P2860
Q28546705-591A9A92-E5FF-4416-9B04-A26E5014BF34Q28547671-0F939073-0A28-4842-A3AA-59FA3F01AEEDQ33851707-6F92B6A4-B3B0-4445-BB52-2630B425A203Q35010647-F6E28ADD-3A67-44C6-90AC-0666834AB722Q35801267-1B351F55-30E7-4702-A2D5-548C7E6F0BFAQ35834474-0FE0296E-CA48-470E-AE0E-93EF39AADEAAQ35973546-29A2D978-C707-48DD-9E17-09B966C9E5F1Q36968066-57352404-3EAE-46F9-B96E-66EACD528252Q37336432-022EB0B8-C454-4DAC-97EB-2A7B79DAFCAEQ37546988-A2C9994B-38E4-4524-9E68-2C6AB2FF7582Q39175156-83064BB8-476F-47BC-87AE-9555831D79E7Q39329214-05DABEAF-3A52-484D-8543-E34D916C783BQ39365643-41B157CE-1555-405C-9AE0-720813B28D80Q40072998-4DAD38C9-6D52-48EE-8702-9936D9CA8FAAQ40207035-F8047F99-CADF-4BB5-920C-2C1A694763B7Q41900816-FC77C2FF-1C0D-47E7-A493-0A5E5E44B047Q55332047-E0ACB233-5978-493E-831A-D61014422B72
P2860
Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency
@en
Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency.
@nl
type
label
Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency
@en
Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency.
@nl
prefLabel
Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency
@en
Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency.
@nl
P2093
P2860
P356
P1433
P1476
Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency
@en
P2093
P2860
P304
P356
10.1128/JVI.00244-10
P407
P577
2010-06-23T00:00:00Z